List view / Grid view
Sublicence agreements signed by the Medicines Patent Pool (MPP) and…
Sublicence agreements signed by the Medicines Patent Pool (MPP) and three generic manufacturers could enable millions to access a long-acting HIV medicine.
The Medicines Patent Pool's 2023-2025 strategy plans to expand medicine…
The Medicines Patent Pool's 2023-2025 strategy plans to expand medicine access by improving the availability of innovative medicines in low- and middle-income countries.
Pfizer’s oral COVID-19 treatment nirmatrelvir will be produced by 35…
Pfizer’s oral COVID-19 treatment nirmatrelvir will be produced by 35 generic manufacturers to increase supply for low- and middle-income countries.
The license agreement between Pfizer and the Medicines Patent Pool…
The license agreement between Pfizer and the Medicines Patent Pool (MPP) will enable access to Pfizer's antiviral candidate in 95 countries.
